Article

Apo D in soft tissue tumors - A novel marker for dermatofibrosarcoma protuberans

Department of Biochemistry, Stanford University, Palo Alto, California, United States
American Journal of Surgical Pathology (Impact Factor: 4.59). 09/2004; 28(8):1063-9. DOI: 10.1097/01.pas.0000126857.86186.4c
Source: PubMed

ABSTRACT Using gene microarray expression profiling, we previously found that apolipoprotein D (Apo D) was highly expressed in dermatofibrosarcoma protuberans (DFSP). In this study, we confirm that Apo D is highly and relatively specifically expressed in DFSP using immunohistochemistry. A tissue microarray containing 421 soft tissue tumors was constructed and stained with antibodies against Apo D and CD34. Cytoplasmic immunostaining for Apo D was found in 9 of 10 typical DFSPs. In addition, 3 of 3 Bednar tumors and 2 of 3 giant cell fibroblastomas stained in conventional sections. In contrast, Apo D was immunoreactive in only a very small subset of a diverse collection of other soft tissue tumors, including Malignant Fibrous Histiocytoma (MFH), glomus tumor, neurofibroma, and malignant peripheral nerve sheath tumors. Immunostains for Apo D were negative in conventional sections of 16 fibrous histiocytomas, and an additional 12 variants of fibrous histiocytoma. Digital images of all immunohistochemical and hematoxylin and eosin tissue microarray stains are available at the accompanying website (http://microarray-pubs.stanford.edu/tma_portal/apod/). We conclude that Apo D is strongly expressed in DFSPs and neural lesions and may be useful in differentiating DFSP from fibrous histiocytoma.

Download full-text

Full-text

Available from: Rajiv Michael Patel, Feb 12, 2015
2 Followers
 · 
168 Views
  • Source
    • "Several others studies using microarray technology had been reported mainly to describe gene expression signature associated with histologic differentiation or outcome in specific histologic subtypes [8] [9] [10] [11] [12] [13] [14] [15] [16]. It is clear that sarcomas have distinct pathways related to malignant transformation and cellular differentiation and some of molecular alterations can be pinpointed to specific chromosomal translocations that are pathognomonic for specific tumors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Soft tissue tumors represent a group of neoplasia with different histologic and biological presentations varying from benign, locally confined to very aggressive and metastatic tumors. The molecular mechanisms responsible for such differences are still unknown. The understanding of these molecular alterations mechanism will be critical to discriminate patients who need systemic treatment from those that can be treated only locally and could also guide the development of new drugs' against this tumors. Using 102 tumor samples representing a large spectrum of these tumors, we performed expression profiling and defined differentially expression genes that are likely to be involved in tumors that are locally aggressive and in tumors with metastatic potential. We described a set of 12 genes (SNRPD3, MEGF9, SPTAN-1, AFAP1L2, ENDOD1, SERPIN5, ZWINTAS, TOP2A, UBE2C, ABCF1, MCM2, and ARL6IP5) showing opposite expression when these two conditions were compared. These genes are mainly related to cell-cell and cell-extracellular matrix interactions and cell proliferation and might represent helpful tools for a more precise classification and diagnosis as well as potential drug targets.
    Translational oncology 02/2010; 3(1):23-32. DOI:10.1593/tlo.09166 · 3.40 Impact Factor
  • Source
    • "Immunohistochemical staining for CD 34 is especially helpful in differential diagnosis of DFSP and dermatofibroma (also called benign fibrous histiocytoma , BFH, histiocytoma). Recently, a novel immunohistochemical marker, apolipoprotein D, which is relatively specific for DFSP, has also been reported to be useful in differential diagnosis of DFSP and dermatofibroma (West et al. 2004). Ring chromosomes containing material from chromosomes 17 and 22 are typical cytogenetic changes in DFSP in adults (Naeem et al. 1995). "
  • Source
    • "Several others studies using microarray technology had been reported mainly to describe gene expression signature associated with histologic differentiation or outcome in specific histologic subtypes [8] [9] [10] [11] [12] [13] [14] [15] [16]. It is clear that sarcomas have distinct pathways related to malignant transformation and cellular differentiation and some of molecular alterations can be pinpointed to specific chromosomal translocations that are pathognomonic for specific tumors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Soft tissue tumors represent a group of neoplasia with different histologic and biological presentations varying from benign, locally confined to very aggressive and metastatic tumors. The molecular mechanisms responsible for such differences are still unknown. The understanding of these molecular alterations mechanism will be critical to discrimi- nate patients who need systemic treatment from those that can be treated only locally and could also guide the de- velopment of new drugs' against this tumors. Using 102 tumor samples representing a large spectrum of these tumors, we performed expression profiling and defined differentially expression genes that are likely to be involved in tumors that are locally aggressive and in tumors with metastatic potential. We described a set of 12 genes (SNRPD3, MEGF9, SPTAN-1, AFAP1L2, ENDOD1, SERPIN5, ZWINTAS, TOP2A, UBE2C, ABCF1, MCM2 ,a ndARL6IP5) showing opposite expression when these two conditions were compared. These genes are mainly related to cell-cell and cell-extracellular matrix interactions and cell proliferation and might represent helpful tools for a more precise classification and diagnosis as well as potential drug targets.
Show more